

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
PREAMBLE.....	7
1. Background.....	9
2. Objective and Scope	9
3. Selection of Topics for Monographs	10
4. Data for Monographs	11
5. The Working Group	11
6. Working Procedures	11
7. Exposure Data.....	12
8. Studies of Cancer in Humans	14
9. Studies of Cancer in Experimental Animals.....	17
10. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms	20
11. Summary of Data Reported	22
12. Evaluation.....	23
13. References.....	28
GENERAL REMARKS	33
THE MONOGRAPHS	37
Smokeless Tobacco	39
1. Description of Smokeless Tobacco Practices	41
1.1 Historical overview.....	41
1.1.1 Tobacco chewing	41
1.1.2 Snuff taking	43
1.1.3 Attitudes and beliefs regarding smokeless tobacco use	46
1.2 Manufacture and use of smokeless tobacco products.....	47
1.2.1 Oral use	49
1.2.2 Nasal use	54
1.3 Chemical composition of smokeless tobacco.....	55
1.3.1 General overview.....	55
1.3.2 Carcinogenic compounds in smokeless tobacco	57
1.3.3 Smokeless tobacco products	60
1.3.4 Kentucky (KY) reference smokeless tobacco products	85
1.3.5 Pesticide residues.....	86

1.4	Production, consumption and prevalence of use of smokeless tobacco products	86
1.4.1	Europe	88
1.4.2	North and South America	98
1.4.3	South Asia	109
1.4.4	Africa	137
1.4.5	Association between smokeless tobacco use and cigarette smoking	144
1.4.6	Occupational exposure to unburnt tobacco	154
1.5	Regulations	156
1.5.1	Framework Convention on Tobacco Control	156
1.5.2	Australia and New Zealand	156
1.5.3	Europe	157
1.5.4	North America	158
1.5.5	Asia	161
1.5.6	Africa	165
2.	Studies of Cancer in Humans	166
2.1	Introduction	166
2.2	Oral use	167
2.2.1	Cancer of the oral cavity and pharynx	167
2.2.2	Precancerous lesions	191
2.2.3	Cancer of the oesophagus	201
2.2.4	Cancer of the pancreas.....	205
2.2.5	Cancers at other sites	209
2.3	Nasal use	229
2.3.1	Cancer of the oral cavity	229
2.3.2	Cancer of the oesophagus	231
2.3.3	Cancer of the paranasal sinus	231
2.3.4	Cancer of the larynx	231
2.3.5	Cancer of the lung	233
3.	Studies of Cancer in Experimental Animals	233
3.1	Tobacco	233
3.1.1	Oral administration	233
3.1.2	Application to the oral mucosa or cheek pouch	234
3.1.3	Skin application	236
3.1.4	Other routes of administration.....	237
3.1.5	Skin application with known carcinogens or modifiers	238
3.2	Snuff tobacco	239
3.2.1	Oral administration	239
3.2.2	Application to the oral mucosa or cheek pouch	240
3.2.3	Subcutaneous administration.....	243
3.2.4	Administration with known carcinogens or modifiers	244

3.3	<i>Bidi</i> tobacco, <i>mishri</i> and <i>naswar</i>	247
3.3.1	<i>Bidi</i> tobacco	247
3.3.2	<i>Mishri</i>	247
3.3.3	<i>Naswar</i>	250
4.	Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms	251
4.1	Absorption, distribution, metabolism and excretion.....	251
4.1.1	Humans	251
4.1.2	Experimental systems	267
4.2	Toxic effects	272
4.2.1	Humans	272
4.2.2	Experimental systems	333
4.3	Reproductive, developmental and hormonal effects	336
4.3.1	Humans	336
4.3.2	Experimental systems	338
4.4	Genetic and related effects	341
4.4.1	Humans	341
4.4.2	Experimental systems	359
4.5	Mechanistic considerations	362
5.	Summary of Data Reported and Evaluation	363
5.1	Exposure data	363
5.2	Human carcinogenicity data	363
5.3	Animal carcinogenicity data	366
5.4	Other relevant data	367
5.5	Evaluation	370
6.	References	370
	Some Tobacco-specific N-Nitrosamines	419
1.	Exposure Data	421
1.1	Chemical and physical data (by compound).....	421
1.2	Technical products and impurities, analysis, production and use	426
1.2.1	Technical products and impurities.....	426
1.2.2	Analysis	426
1.2.3	Production	427
1.2.4	Use	427
1.3	Occurrence	427
1.3.1	Fresh tobacco	429
1.3.2	Cured tobacco	429
1.3.3	Cigarette tobacco	431
1.3.4	Mainstream cigarette smoke	436
1.3.5	Sidestream cigarette smoke	442
1.3.6	Other smoked tobacco products	442

1.3.7	Secondhand tobacco smoke.....	444
1.3.8	Smokeless tobacco products	444
1.4	Biomonitoring in saliva, urine and other tissues	451
1.4.1	4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and its metabolites	451
1.4.2	<i>N'</i> -Nitrosonornicotine (NNN)	455
1.4.3	<i>N'</i> -Nitrosoanabasine (NAB)	456
1.4.4	<i>N'</i> -Nitrosoanatabine (NAT)	456
2.	Studies of Cancer in Humans	457
3.	Studies of Cancer in Experimental Animals	457
3.1	4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)	457
3.1.1	Intraperitoneal administration	457
3.1.2	Intravesicular administration	460
3.1.3	Administration in the drinking-water	460
3.1.4	Oral cavity swabbing.....	461
3.1.5	Cheek pouch application	461
3.1.6	Subcutaneous administration.....	461
3.1.7	Transplacental or neonatal exposure	464
3.1.8	Administration with known carcinogens or modifying factors.....	467
3.1.9	Carcinogenicity of NNK metabolites	468
3.2	4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)	468
3.2.1	Intraperitoneal administration	469
3.2.2	Administration in the drinking-water	470
3.2.3	Administration with known carcinogens or modifying factors.....	470
3.3	<i>N'</i> -Nitrosonornicotine (NNN)	471
3.3.1	Intraperitoneal administration	471
3.3.2	Skin application	473
3.3.3	Oral administration	473
3.3.4	Cheek pouch application	474
3.3.5	Subcutaneous administration.....	475
3.3.6	Administration with known carcinogens or modifying factors.....	476
3.3.7	Carcinogenicity of NNN metabolites	477
3.4	<i>N'</i> -Nitrosoanabasine (NAB)	478
3.4.1	Intraperitoneal administration	478
3.4.2	Administration in the drinking-water	479
3.4.3	Subcutaneous administration.....	479
3.5	<i>N'</i> -Nitrosoanatabine (NAT).....	479
4.	Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanism	480
4.1	Absorption, distribution, metabolism and excretion.....	480
4.1.1	Humans	480
4.1.2	Experimental systems	502

CONTENTS

ix

4.2	Toxic effects	530
4.2.1	Humans	530
4.2.2	Experimental systems	531
4.3	Reproductive and developmental effects	531
4.4	Genetic and related effects	532
4.4.1	Humans	532
4.4.2	Experimental systems	532
4.5	Mechanistic considerations	543
4.5.1	4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK).....	543
4.5.2	<i>N'</i> -Nitrosornicotine (NNN)	548
5.	Summary of Data Reported and Evaluation	548
5.1	Exposure data	548
5.2	Human carcinogenicity data	549
5.3	Animal carcinogenicity data	549
5.4	Other relevant data	551
5.5	Evaluation	553
6.	References	553
GLOSSARY		585
LIST OF ABBREVIATIONS		589
CUMULATIVE INDEX TO THE <i>MONOGRAPHS</i> SERIES		593

NOTE TO THE READER

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer under some circumstances. The *Monographs* evaluate cancer hazards, despite the historical presence of the word ‘risks’ in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Carcinogen Identification and Evaluation Group, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Carcinogen Identification and Evaluation Group, so that corrections can be reported in future volumes.